1428566-42-0Relevant articles and documents
Triazolopyridazine LRRK2 kinase inhibitors
Franzini, Maurizio,Ye, Xiaocong M.,Adler, Marc,Aubele, Danielle L.,Garofalo, Albert W.,Gauby, Shawn,Goldbach, Erich,Probst, Gary D.,Quinn, Kevin P.,Santiago, Pam,Sham, Hing L.,Tam, Danny,Truong, Anh,Ren, Zhao
, p. 1967 - 1973 (2013/04/24)
Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [